Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Blood (2024) 144 (4): 392–401.

https://doi.org/10.1182/blood.2024023847

Published: 2024

Includes: Supplemental data

Journal Articles

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Blood (2021) 138 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2021-146494

Published: 2021

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study

Blood (2018) 132 (Supplement 1): 707.

https://doi.org/10.1182/blood-2018-99-113906

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

Kai Huebel, MD, Alessandro Re, MD, Ariane Boumendil, PhD, Herve Finel, Marcus Hentrich, Mariagrazia Michieli, Edward Kanfer, Jose Luis Diez-Martin, MD PhD, Pascual Balsalobre, Laure Vincent, Wilfried Schroyens, MD PhD, Josep Maria Ribera Santasusana, Nicolaus Kröger, MD, Xaver Schiel, MD, Kirsty J Thomson, MD, Jorge Sierra, MD, Aida Botelho Sousa, Silvia Montoto, MD, Peter Dreger, MD

Blood (2016) 128 (22): 2257.

https://doi.org/10.1182/blood.V128.22.2257.2257

Published: 2016

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Aristeidis Chaidos, Scott Patterson, Richard Szydlo, Mohammed Suhail Chaudhry, Francesco Dazzi, Edward Kanfer, Donald McDonald, David Marin, Dragana Milojkovic, Jiri Pavlu, John Davis, Amin Rahemtulla, Katy Rezvani, John Goldman, Irene Roberts, Jane Apperley, Anastasios Karadimitris

Blood (2012) 119 (21): 5030–5036.

https://doi.org/10.1182/blood-2011-11-389304

Published: 2012

Includes: Supplemental data

Journal Articles

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Ian H. Gabriel, Ruhena Sergeant, Richard Szydlo, Jane F. Apperley, Hugues deLavallade, Abdullah Alsuliman, Ahmad Khoder, David Marin, Edward Kanfer, Nichola Cooper, John Davis, Donald MacDonald, Marco Bua, Letizia Foroni, Chrissy Giles, Dragana Milojkovic, Amin Rahemtulla, Katayoun Rezvani

Blood (2010) 116 (12): 2033–2039.

https://doi.org/10.1182/blood-2010-03-273706

Published: 2010

Journal Articles

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Holger W Auner, Hilda Owiti, Chrissy Giles, Jiri Pavlu, Donald MacDonald, Edward Kanfer, Jane F Apperley, Amin Rahemtulla

Blood (2009) 114 (22): 1781.

https://doi.org/10.1182/blood.V114.22.1781.1781

Published: 2009

Journal Articles

Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.

Aristeidis Chaidos, MD, PhD, Chrissy Giles, B.A.(Hons), Holger W Auner, Marco Bua, Jiri Pavlu, Ellena Smith, Edward Kanfer, MD, Donald MacDonald, Jane F. Apperley, MBChB, FRCP, FRCPath, Amin Rahemtulla, MBBS, PhD, FRCP

Blood (2009) 114 (22): 1229.

https://doi.org/10.1182/blood.V114.22.1229.1229

Published: 2009

Journal Articles

Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience.

Anna Babb, Nadine Farah, Jane Apperley, John Goldman, Edward Kanfer, David Marin, Dragana Milojkovic, Amin Rahemtulla, Katy Rezvani, Nina Salooja

Blood (2009) 114 (22): 2257.

https://doi.org/10.1182/blood.V114.22.2257.2257

Published: 2009

Journal Articles

Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.

Ian H Gabriel, Dr, Ruhena Sargent, Dr, Hugues de Lavallade, Richard Szydlo, Jane Apperley, Ahmad Khoder, Dr, Abdullah Alsuliman, David Marin, Letizia Foroni, John Davis, Chrissy Giles, Edward Kanfer, MD, Amin Rahemtulla, MBBS, PhD, FRCP, Katayoun Rezvani, MD, PhD

Blood (2009) 114 (22): 2840.

https://doi.org/10.1182/blood.V114.22.2840.2840

Published: 2009

Journal Articles

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Ian H Gabriel, Juliet Sharon, Eduardo Olavarria, MD, Amin Rahemtulla, Edward Kanfer, David Marin, Dragana Milojkovic, Katayoun Rezvani, MD, PhD, Donald MacDonald, Richard M. Szydlo

Blood (2008) 112 (11): 2378.

https://doi.org/10.1182/blood.V112.11.2378.2378

Published: 2008

Journal Articles

Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response

Edward D. Seaton, Richard M. Szydlo, Edward Kanfer, Jane F. Apperley, Robin Russell-Jones

Blood (2003) 102 (4): 1217–1223.

https://doi.org/10.1182/blood-2002-11-3351

Published: 2003

Journal Articles

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

Jyoti Wadhwa, Richard M. Szydlo, Jane F. Apperley, Andrew Chase, Marco Bua, David Marin, Eduardo Olavarria, Edward Kanfer, John M. Goldman

Blood (2002) 99 (7): 2304–2309.

https://doi.org/10.1182/blood.V99.7.2304

Published: 2002

Journal Articles

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Eduardo Olavarria, Edward Kanfer, Richard Szydlo, Jaspal Kaeda, Katayoun Rezvani, Kate Cwynarski, Christopher Pocock, Francesco Dazzi, Charles Craddock, Jane F. Apperley, Nicholas C. P. Cross, John M. Goldman

Blood (2001) 97 (6): 1560–1565.

https://doi.org/10.1182/blood.V97.6.1560

Published: 2001

NARROW

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.

Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.

Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience.

Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.

Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies

Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only